^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

VTP-800

i
Other names: VTP-800, ChAdOx1-MVA 5T4, ChAdOx1.5T4, VTP800, VTP 800
Associations
Trials
Company:
Barinthus Bio, University of Oxford
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
over4years
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. (PubMed, J Immunother Cancer)
An excellent safety profile and T-cell responses elicited in the circulation and also detected in the prostate gland support the evaluation of the ChAdOx1-MVA 5T4 vaccine in efficacy trials. It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab.
Clinical • P1 data • Journal
|
CD8 (cluster of differentiation 8) • KLK3 (Kallikrein-related peptidase 3)
|
TILs
|
Opdivo (nivolumab) • Provenge (sipuleucel-T) • TroVax (MVA 5T4) • VTP-800